MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. SNDA
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Sonida Senior Living (SNDA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Sonida Senior Living
NYSE•Healthcare•Medical Care Facilities
$39.43-0.26(-0.01%)Pre-market
Market Cap
$1.86B
P/S
3.5x
P/B
2.1x

Sonida Senior Living, Inc. owns and operates senior housing communities in the United States. The company provides independent living services, which include daily meals, transportation, social and recreational activities, laundry, housekeeping, and 24-hour staffing; and access to health screenings, periodic special services, and dietary and similar programs, as well as exercise and fitness classes. It offers assisted living services consist of personal care services, such as assistance with activities of daily living, including ambulation, bathing, dressing, eating, grooming, personal hygiene, and monitoring or assistance with medications; support services, such as meals, assistance with social and recreational activities, laundry, general housekeeping, maintenance, and transportation services; and supplemental services, which include extra transportation, personal maintenance, and extra laundry services, as well as special care services for residents with various forms of dementia. In addition, it offers memory care services; and home care services through third-party providers, such as customized physician, dentistry, podiatry, and other health-related rehabilitation and therapy services. Further, it provides respite care and temporary care and therapy programs. The company was formerly known as Capital Senior Living Corporation and changed its name to Sonida Senior Living, Inc. in November 2021. Sonida Senior Living, Inc. was founded in 1990 and is based in Dallas, Texas.

C

How this company scores

AverageMetricSide Score: 41/100

Strongest: Growth (16/25); weakest: Cash & Earnings Quality (4/25).

Profitability7/25
Growth16/25
Balance Sheet & Red Flags14/25
Cash & Earnings Quality4/25
Strengths
Growing revenueImproving leverageConsistent growthImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 9.9x5y range 0.6x – 9.9x
P/E 9.9x · above its 4-quarter median

Currently above its 4-quarter median.

P/S · 3.5x5y range 0.2x – 3.5x
P/S 3.5x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 2.1x5y range 0.9x – 117.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $1.86B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$525.97M
7Q
Q. Revenue
$207.65M
2Q
TTM EBITDA
$-30.36M
480%
TTM Op. Income
$-122.94M
6Q
Q. Op. Income
$-24.38M
123%
TTM Net Income
$-122.38M
4Q
Q. Net Income
$-24.46M
1465%
EPS
$-0.52
225%
Shares Out.
$46.81M
6Q
$525.97M in TTM revenue grew 49.4% YoY, reaching $207.65M last quarter. TTM EBITDA of $-30.36M and TTM operating income of $-122.94M show growth is flowing through to the bottom line. However, net income is negative at $122.38M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
9.1%
214%
Op. Margin
-11.7%
0%
Net Margin
-11.8%
605%
Op. margin of -11.7% is down 0.0% YoY — costs are rising relative to revenue. Net margin at -11.8% Over the past year, operating margin is down 0% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
3.5x
6Q
P/B Ratio
2.1x
70%
P/S of 3.5x and P/B of 2.1x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$2.55B
200%
Cash
$48.71M
247%
Long-Term Debt
$1.56B
7Q
Book Value
$866.21M
1286%
D/E Ratio
1.8
83%
Debt/EBITDA
82.7
2Q
With $2.55B in assets and $1.56B in long-term debt, D/E is 1.8and book value is $866.21M — moderate leverage. Over the past year, debt/equity is down 83% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$8.72M
2%
TTM Free Cash Flow
$-52.71M
2Q
FCF Margin
-10.0%
96%
FCF / Net Income
0.4
20%
TTM FCF of $-52.71M on $8.72M in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 2.1x
· below its 8-quarter median

Currently below its 8-quarter median.

Cash Burn

Watch

6 of the last 8 quarters had negative FCF — inconsistent cash generation raises sustainability concerns.

Share Dilution

Red Flag

Shares outstanding increased 202.8% — significant dilution, likely from stock compensation or capital raises.